---
title: "DSNKY.US (DSNKY.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DSNKY.US/news.md"
symbol: "DSNKY.US"
name: "DSNKY.US"
parent: "https://longbridge.com/en/quote/DSNKY.US.md"
datetime: "2026-05-20T22:54:19.907Z"
locales:
  - [en](https://longbridge.com/en/quote/DSNKY.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DSNKY.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DSNKY.US/news.md)
---

# DSNKY.US (DSNKY.US) — Related News

### [FDA approves Enhertu for two HER2-positive early breast cancer indications](https://longbridge.com/en/news/286740066.md)
*2026-05-18T07:49:17.000Z*
> A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings.

### [<![CDATA[FDA Expands Enhertu in Early HER2-Positive Breast Cancer]]>](https://longbridge.com/en/news/286780814.md)
*2026-05-18T13:11:58.000Z*
> The FDA has expanded the use of Enhertu (trastuzumab deruxtecan) for HER2-positive Stage II and III breast cancer, appro

### [AZN :FDA Approves ENHERTU For HER2-Positive Early Breast Cancer In Neoadjuvant And Adjuvant Settings](https://longbridge.com/en/news/286677080.md)
*2026-05-17T15:50:46.000Z*
> The FDA has approved AstraZeneca and Daiichi Sankyo's ENHERTU for neoadjuvant and adjuvant treatment of HER2-positive ea

### [Key facts: Enhertu Cleared for Two Breast Uses; Safety Flag on AZ RSV](https://longbridge.com/en/news/286637657.md)
*2026-05-16T07:14:55.000Z*
> FDA cleared Enhertu for two more Stage 2–3 breast cancer uses. AstraZeneca co-develops/commercializes the drug and owes 

### [Daiichi Sankyo (OTCMKTS:DSNKY) Announces Earnings Results](https://longbridge.com/en/news/285980035.md)
*2026-05-11T18:00:38.000Z*
> Daiichi Sankyo (OTCMKTS:DSNKY) announced its quarterly earnings, reporting an EPS of $0.15, a net margin of 14.83%, and 

### [Daiichi Sankyo (OTCMKTS:DSNKY) Issues FY 2026 Earnings Guidance](https://longbridge.com/en/news/285959341.md)
*2026-05-11T14:19:25.000Z*
> Daiichi Sankyo (OTCMKTS:DSNKY) has updated its FY 2026 earnings guidance, projecting EPS of 0.910, below the consensus e

### [Daiichi Sankyo Earnings Fall; Guides FY27](https://longbridge.com/en/news/285895666.md)
*2026-05-11T07:07:26.000Z*
> Daiichi Sankyo Co. Ltd. reported a 12.1% decline in net income for the fiscal year ending March 31, 2026, with profit at

### [Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation](https://longbridge.com/en/news/285893113.md)
*2026-05-11T06:45:24.000Z*
> Daiichi Sankyo has unveiled a new Five-Year Business Plan (FY2026 - FY2030) aimed at achieving over 2.3 trillion yen in 

### [Daiichi Sankyo and Waiv partner for ADC biomarkers](https://longbridge.com/en/news/285532705.md)
*2026-05-07T09:03:01.000Z*
> A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings.